Press Releases
At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 10, 2024
$16.3 million in cash and cash equivalents at the end of Q1 2024 providing projected cash runway into Q1 2026 Third amendment made in Q1 to Cipla partnership results in the wind down of the...
-
Mar 28, 2024
2023 year-end $19.2 million cash and cash equivalents provide projected cash runway into Q1 2026 3rd amendment to Cipla partnership resulted in the wind down of the PUR1900 Phase 2b study and a...
-
Jan 8, 2024
Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to approval, in exchange for 2% royalty on net sales payable to...
-
Nov 9, 2023
Patient enrollment for the Phase 2b study of PUR1900 is ongoing with four additional sites added during Q3, totaling seventeen active sites to date in four countries; topline data anticipated in...
-
Sep 19, 2023
Pulmatrix received a study may proceed letter for a Phase 2 Study to Evaluate PUR3100, an orally inhaled dry powder formulation of dihydroergotamine ("DHE") in the treatment of acute migraine...
